292 related articles for article (PubMed ID: 22698482)
1. The neuroprotective effect of the GSK-3β inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice.
Ahn SW; Kim JE; Park KS; Choi WJ; Hong YH; Kim SM; Kim SH; Lee KW; Sung JJ
J Neurol Sci; 2012 Sep; 320(1-2):1-5. PubMed ID: 22698482
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis.
Ahn SW; Jeon GS; Kim MJ; Shon JH; Kim JE; Shin JY; Kim SM; Kim SH; Ye IH; Lee KW; Hong YH; Sung JJ
J Neurol Sci; 2014 May; 340(1-2):112-6. PubMed ID: 24680562
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS.
Koh SH; Kim Y; Kim HY; Hwang S; Lee CH; Kim SH
Exp Neurol; 2007 Jun; 205(2):336-46. PubMed ID: 17433298
[TBL] [Abstract][Full Text] [Related]
4. Extrinsic Apoptosis Pathway Altered by Glycogen Synthase Kinase-3
Kim JE; Lim JH; Jeon GS; Shin JY; Ahn SW; Kim SH; Lee KW; Hong YH; Sung JJ
Biomed Res Int; 2017; 2017():4163839. PubMed ID: 29082245
[TBL] [Abstract][Full Text] [Related]
5. Role of GSK-3beta activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene.
Koh SH; Lee YB; Kim KS; Kim HJ; Kim M; Lee YJ; Kim J; Lee KW; Kim SH
Eur J Neurosci; 2005 Jul; 22(2):301-9. PubMed ID: 16045483
[TBL] [Abstract][Full Text] [Related]
6. Effect of JGK-263 as a new glycogen synthase kinase-3β inhibitor on extrinsic apoptosis pathway in motor neuronal cells.
Jeon GS; Kim JE; Ahn SW; Park KS; Hong YH; Ye IH; Park JS; Kim SH; Lee KW; Kim SM; Sung JJ
Biochem Biophys Res Commun; 2013 Sep; 439(2):309-14. PubMed ID: 23899525
[TBL] [Abstract][Full Text] [Related]
7. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL
Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224
[TBL] [Abstract][Full Text] [Related]
8. Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice.
Holasek SS; Wengenack TM; Kandimalla KK; Montano C; Gregor DM; Curran GL; Poduslo JF
Brain Res; 2005 May; 1045(1-2):185-98. PubMed ID: 15910777
[TBL] [Abstract][Full Text] [Related]
9. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis.
Takata M; Tanaka H; Kimura M; Nagahara Y; Tanaka K; Kawasaki K; Seto M; Tsuruma K; Shimazawa M; Hara H
Br J Pharmacol; 2013 Sep; 170(2):341-51. PubMed ID: 23763343
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective Effect of Human Adipose Stem Cell-Derived Extract in Amyotrophic Lateral Sclerosis.
Jeon GS; Im W; Shim YM; Lee M; Kim MJ; Hong YH; Seong SY; Kim M; Sung JJ
Neurochem Res; 2016 Apr; 41(4):913-23. PubMed ID: 26646002
[TBL] [Abstract][Full Text] [Related]
12. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model.
Feng HL; Leng Y; Ma CH; Zhang J; Ren M; Chuang DM
Neuroscience; 2008 Aug; 155(3):567-72. PubMed ID: 18640245
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation.
Koh SH; Kim Y; Kim HY; Cho GW; Kim KS; Kim SH
Eur J Neurosci; 2007 Apr; 25(7):1923-30. PubMed ID: 17439481
[TBL] [Abstract][Full Text] [Related]
14. c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis.
Katsumata R; Ishigaki S; Katsuno M; Kawai K; Sone J; Huang Z; Adachi H; Tanaka F; Urano F; Sobue G
PLoS One; 2012; 7(9):e46185. PubMed ID: 23049975
[TBL] [Abstract][Full Text] [Related]
15. Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis.
Martínez-González L; Gonzalo-Consuegra C; Gómez-Almería M; Porras G; de Lago E; Martín-Requero Á; Martínez A
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445680
[TBL] [Abstract][Full Text] [Related]
16. Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model.
Fellner A; Barhum Y; Angel A; Perets N; Steiner I; Offen D; Lev N
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28763002
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of IGF-I and GSK in the spinal cord of Kii and Guamanian ALS patients.
Kihira T; Suzuki A; Kondo T; Wakayama I; Yoshida S; Hasegawa K; Garruto RM
Neuropathology; 2009 Oct; 29(5):548-58. PubMed ID: 19323791
[TBL] [Abstract][Full Text] [Related]
18. Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice.
Petri S; Kiaei M; Wille E; Calingasan NY; Flint Beal M
J Neurol Sci; 2006 Dec; 251(1-2):44-9. PubMed ID: 17049562
[TBL] [Abstract][Full Text] [Related]
19. n-butylidenephthalide treatment prolongs life span and attenuates motor neuron loss in SOD1
Zhou QM; Zhang JJ; Li S; Chen S; Le WD
CNS Neurosci Ther; 2017 May; 23(5):375-385. PubMed ID: 28229532
[TBL] [Abstract][Full Text] [Related]
20. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy.
Dachs E; Piedrafita L; Hereu M; Esquerda JE; Calderó J
Neuroscience; 2013 Oct; 250():417-33. PubMed ID: 23876328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
